Abstract
Targeted therapies are an efficacious treatment option for patients with advanced renal cell carcinoma (RCC) or hepatocellular carcinoma (HCC). Targeted therapies often have low-grade toxicities that may not require intervention but may be persistent and difficult to live with, thus affecting patients’ quality of life and adherence to treatment. Patient-reported outcomes (PROs) are key indicators of health status and functioning, coming directly from the patient. Comprehensive monitoring of PROs enables implementation of person-centred care.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
